Fed. Circ. Unsure Vanda's Sleep Med Hetlioz Is Patentable

By Katie Buehler (March 14, 2023, 6:17 PM EDT) -- A Federal Circuit panel seemed wary Tuesday of Vanda Pharmaceuticals' attempt to overturn a Delaware federal judge's decision invalidating four patents related to its sleep disorder treatment drug Hetlioz, questioning whether the drug's dosage and method of administration were obvious before the patents were issued....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!